| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 64,20 | 64,50 | 15:48 | |
| 63,92 | 64,76 | 15:48 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 76,00 | 10 | |||
| 75,00 | 15 | |||
| 67,14 | 135 | |||
| 66,88 | 378 | |||
| 65,92 | 3.000 | |||
| 65,60 | 1.500 | |||
| 65,36 | 378 | |||
| 65,02 | 300 | |||
| 64,64 | 155 | |||
| 64,62 | 238 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/kk3a.htm [/URL] | ||||
| 435 | 62,82 | |||
| 135 | 62,80 | |||
| 300 | 62,78 | |||
| 135 | 62,76 | |||
| 1.500 | 62,48 | |||
| 3.000 | 62,40 | |||
| 161 | 62,36 | |||
| 1.500 | 62,30 | |||
| 3.000 | 62,08 | |||
| 180 | 61,96 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 10.346 | 0,590 | 6.109 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | +0,20 +0,31 % | 15 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:36 | Cytokinetics, Incorporated: Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program | 79 | GlobeNewswire (Europe) | Program Provides Communications and Outreach Support for Patient Advocacy Organizations Focused on Cardiovascular Diseases Deadline for Applications is October 2, 2026 SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen | |
| Fr | If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today | 3 | Benzinga.com | ||
| Fr | Cantor Fitzgerald reiterates Overweight on Cytokinetics stock | 2 | Investing.com | ||
| CYTOKINETICS Aktie jetzt für 0€ handeln | |||||
| Mi | Cytokinetics auf Citigroup-Konferenz: Expansion bei HCM soll Wachstum treiben | 1 | Investing.com Deutsch | ||
| 02.09. | Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? | 6 | Zacks |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 14:10 | BioNTech-Aktie: Bei 81,30 € ein Kauf? | sharedeals.de | Die BioNTech-Aktie bleibt ein Spielball zwischen vielversprechender Onkologie-Pipeline und tiefgreifendem Konzernumbau. Nach dem jüngsten Kurssprung bis knapp 100 € folgte bereits wieder ein kräftiger... ► Artikel lesen | |
| 14:10 | Evaxion applies its AI-Immunology platform in autoimmune diseases | GlobeNewswire (Europe) | Autoimmune diseases are characterized by high unmet medical need with most current treatments only addressing symptoms. Evaxion will apply AI-Immunology to target underlying pathologiesThe unique capabilities... ► Artikel lesen | |
| 14:06 | Akebia Therapeutics, Inc.: Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases | GlobeNewswire (Europe) | Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 13:06 | NRx Pharmaceuticals, Inc.: GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS) | GlobeNewswire (Europe) | Invention is based on the discovery that ALS may be caused by reactivation of Human Endogenous Retrovirus K (HERV K) Envelope protein (K Env), already coded in the "dark genome" of all people. K Env... ► Artikel lesen | |
| 14:50 | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD Goes Live on Immix with ROSA & RIO | Newsfile | ROSA and the RIO Platform Integration with Immix Now Available for Use, with the Nation's Largest Guarding and Monitoring Companies EngagedDetroit, Michigan--(Newsfile Corp. - September 14, 2026) -... ► Artikel lesen |